Julien Taieb, MD, discusses the importance of combining fluoropyrimidines with bevacizumab, key findings from the SUNLIGHT trial and the post-hoc analysis, and how these results may shake up the colorectal cancer treatment paradigm.
CHICAGO — Administering modified FOLFIRINOX chemotherapy before chemoradiation, surgery and adjuvant chemotherapy improved survival outcomes of patients with locally advanced rectal cancer, according to results of the PRODIGE 23 trial.“The most important point of PRODIGE 23 is the overall survival benefit,” Thierry Conroy, MD, of the department of medical oncology at Institut de
email article
Adding neoadjuvant chemotherapy to preoperative chemoradiotherapy (CRT) for locally advanced rectal cancer led to better disease-free survival (DFS) and less toxicity as compared with a standard regimen of neoadjuvant CRT and adjuvant therapy, a randomized trial showed.
DFS at 3 years improved from 69% with standard treatment to 76% with neoadjuvant chemotherapy followed by chemoradiotherapy (CRT) before surgery. Grade 3/4 adverse events (AEs) associated with adjuvant chemotherapy occurred substantially less often in patients who received neoadjuvant chemotherapy, as reported in The significantly improved disease-free survival in the neoadjuvant chemotherapy group and the reduced toxicity indicate that the perioperative approach is more efficient and better tolerated than adjuvant chemotherapy is. Therefore, these results could change clinical practice, concluded Thierry Conroy, MD, of the Cancer Institute of Lorraine in France, and colleagues.